# Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy

Study · id `cardio:ct-nct02405377` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02405377](<https://clinicaltrials.gov/study/NCT02405377>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02405377

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 264 participants.

## Technical summary

Registry record NCT02405377. Randomized; triple masking; primary purpose prevention. Start 2014-02 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 264 participants (enrolled count; ClinicalTrials.gov record NCT02405377, source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02405377, source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)
- Primary completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02405377, source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)
- Completion: 2015-02 (actual) (ClinicalTrials.gov record NCT02405377, source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02405377, source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02405377-2015-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
- Condition: Cardio-Renal Syndrome
- Intervention (Procedure): hydration
- Intervention (Drug): Visipaque
- Intervention (Drug): 0.9% sodium chloride ﬂuid administration
- Intervention (Device): 5-French catheter
- Lead sponsor: Chinese PLA General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Prevention of Contrast-Induced Nephropathy by Central Venous Pressure-Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients (`cardio:pubmed-26685074`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 16ae1a2389850fb9cd48fd79a56cdc7931adf1b78f40d0d24a0004a070b3e08d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
